Marksans Pharma Limited (MARKSANS) — Announcement | 13 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Company uploaded audio recording of investor conference call
💡 Investor Takeaway
Shareholders can now access the full discussion of Q1FY27 results via the company's website.

Marksans Pharma announced it has uploaded the audio recording of today's investor conference call discussing Q1FY27 financial results on its website, making it accessible to shareholders and analysts for review.

📄 View Original Announcement (PDF)

About Marksans Pharma Limited (MARKSANS)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹14,634.92 Cr P/E: 28.3 ROE: 17.2% ROCE: 23.4% Div Yield: 0.28%

View full MARKSANS stock details →

📡 Get AI alerts when MARKSANS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MARKSANS — Free

📊 More MARKSANS filings

See all MARKSANS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MARKSANS files new disclosures

Track MARKSANS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MARKSANS — Free

Free account · 2 AI queries/day